<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04690036</url>
  </required_header>
  <id_info>
    <org_study_id>PD-1,reactive EBV</org_study_id>
    <nct_id>NCT04690036</nct_id>
  </id_info>
  <brief_title>PD-1 Antibody for Reactive EBV After BMT</brief_title>
  <official_title>Reactivation of EBV for Patients With CAEBV and EBV Associated HLH After Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      PD-1 antibody for reactivation of EBV after transplantation in patients with CAEBV/EBV-HLH&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transplantaion is recongnized as a cure for CAEBV and EBV associated HLH，however, many&#xD;
      patients undergo the reactivation of EBV after transpaltion, patiens may at high risk for&#xD;
      recurrence of the disease. PD-1 is a promising therapy to solve this problem.&#xD;
&#xD;
      The present study was a one-arm clinical study, the main subject is to evaluate the effect of&#xD;
      PD-1 antibody on the clearance of EBV&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EBV-DNA turn negative</measure>
    <time_frame>4 weeks after PD-1 antibody was used</time_frame>
    <description>after treatment, the EBV-DNA copies can not be detected in peripheral blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>4 weeks after PD-1 antibody was used</time_frame>
    <description>Adverse events including thyroid function，liver function damage, myelosuppression, infection, bleeding and so on</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Survival</measure>
    <time_frame>1 year</time_frame>
    <description>From enrollment until death or the end of the experiment</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>PD-1</condition>
  <condition>EBV Infection</condition>
  <condition>Transplant</condition>
  <arm_group>
    <arm_group_label>one group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients encountered EBV reactivation after allo-HCT could be enrolled in this study, there was only one group of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>toripalimab injection</intervention_name>
    <description>when EBV-DNA is positive after allo-HCT, and EBV infected T/NK cell, one dose of toripalimab 3mg/kg would be used, the same dose would be repeated 4 weeks later.</description>
    <arm_group_label>one group</arm_group_label>
    <other_name>EBV-DNA positive</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Meet hemophagocytic lymphohistiocytosis (HLH)-04 diagnostic criteria; EBV-DNA in&#xD;
             peripheral blood or EBER in tissue were positive, patients were diagnosed with EBV&#xD;
             associated HLH (EBV-HLH). Chronic active EBV infection (CAEBV) was diagnosed by WHO&#xD;
             criteria.&#xD;
&#xD;
          2. Undergo allo-HCT, have achieved full chimerism&#xD;
&#xD;
          3. Age &gt;18 years old, gender is not limited.&#xD;
&#xD;
          4. After transplantation, EBV was reactivated and EBV-DNA was positive in blood&#xD;
&#xD;
          5. No secondary graft failure. (After grafted, ANC &lt;0.5*10^9/l,PLT &lt;10*10^9/l)&#xD;
&#xD;
          6. No uncontrollable infection&#xD;
&#xD;
          7. Withdraw immunosuppressor, no graft-versus-host disease was observed.&#xD;
&#xD;
          8. Before the start of the study, aminopherase (ALT/AST) and total bilirubin were normal.&#xD;
             Serum creatinine ≤ 1.5 times the upper limit of Normal (ULN); No thyroid dysfunction.&#xD;
             The left ventricular ejection fraction (LVEF) was normal.&#xD;
&#xD;
          9. Informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic to toripalimab&#xD;
&#xD;
          2. Serious immunoreaction: myocardial damage, hepatitis, pneumonia&#xD;
&#xD;
          3. Central nervous system symptoms&#xD;
&#xD;
          4. Serious mental illness;&#xD;
&#xD;
          5. Active bleeding of the internal organs&#xD;
&#xD;
          6. Pancreatitis history. Patients unable to comply during the trial and/or follow-up&#xD;
             phase;&#xD;
&#xD;
          7. Participate in other clinical research at the same time.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhao Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhao Wang</last_name>
    <phone>86-010-63139862</phone>
    <email>wangzhao@ccmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yahong You</last_name>
    <phone>16810283962</phone>
    <email>15332022659@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 27, 2020</study_first_submitted>
  <study_first_submitted_qc>December 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>June 27, 2021</last_update_submitted>
  <last_update_submitted_qc>June 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Zhao Wang</investigator_full_name>
    <investigator_title>Department of Hematology, Beijing Friendship Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epstein-Barr Virus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

